TRPML1 (mucolipin-1/MCOLN1) is predicted to be an intracellular late endosomal and lysosomal ion channel protein belonging to the mucolipin subfamily of Transient Receptor Potential (TRP) proteins [1] [2] [3] . Mutations in the human TRPML1 gene cause mucolipidosis type IV disease (ML4) 4, 5 . ML4 patients exhibit motor impairment, mental retardation, retinal degeneration, and iron-deficiency anemia. Since aberrant iron metabolism may cause neural and retinal degeneration 6, 7 , it may be a primary cause of ML4 phenotypes. In most mammalian cells, release of iron from endosomes and lysosomes following iron uptake via endocytosis of Fe 3+ -bound transferrin receptors 6 , or following lysosomal degradation of ferritin-Fe complexes and autophagic ingestion of iron-containing macromolecules 6, 8 , is the major source of cellular iron. The Divalent Metal Transporter protein (DMT1) is the only endosomal Fe 2+ transporter currently known and is highly expressed in erythroid precursors 6, 9 , but genetic studies suggest the existence of a DMT1-independent endosomal/lysosomal Fe 2+ transport protein 9 . Here, by measuring radiolabeled iron uptake, monitoring the levels of cytosolic and intra-lysosomal iron and directly patch-clamping the late endosomal/lysosomal membrane, we show that TRPML1 functions as a Fe 2+ permeable channel in late endosomes and lysosomes. ML4 mutations are shown to impair TRPML1's ability to permeate Fe 2+ at varying degrees, which correlate well with the disease severity. A comparison of TRPML1 −/− ML4 and control skin fibroblasts showed a reduction of cytosolic Fe 2+ levels, an increase of intra-lysosomal Fe 2+ levels, and an accumulation of lipofuscin-like molecules in TRPML1 −/− cells. We propose that TRPML1 mediates a mechanism by which Fe 2+ is released from late endosomes/lysosomes. Our results suggest that impaired iron transport may contribute to both hematological and degenerative symptoms of ML4 patients.
Keywords iron transport; calcium channel; transient receptor potential (TRP) channel; iron-deficiency; anemia; patch clamp; whole-lysosome recording; lumenal-side-out patch; mucolipidosis; ML4; endosomes; lysosomes; lipofuscin; aging pigment; free radical oxide Release of Fe 2+ from late endosomes and lysosomes into the cytosol is essential for cellular iron metabolism (see Supplementary Fig. 1 ) 6 . Since TRPML1 is ubiquitously expressed (in cells of every tissue) 5 and primarily localized in the late endosome/lysosome (LE/ Ly) 1, 3, 10 , we hypothesize that TRPML1 may serve as a novel endo-lysosomal Fe 2+ release channel. The intracellular localization of wild-type (wt) TRPML1 1, 3, 10 (also see Supplementary Fig. 2 ), however, makes it difficult to assay TRPML1's channel function. To overcome this problem, we recently developed a functional assay for TRPML channels 11 . A spontaneous mouse mutation (A419P) 12 dramatically increases TRPML3-mediated currents at the plasma membrane without altering its permeation properties 11 . Mice carrying this mutation (Varitint-Waddler, Va) are deaf and exhibit skin pigmentation defects. When the Va mutation (proline substitution) was introduced into a homologous position in TRPML1 (V432P), the mutant channel TRPML1 Va was (mis-)localized in many cellular compartments including both LE/Ly and the plasma membrane ( Supplementary Fig. 2 ). Importantly, TRPML1 Va , but not wt TRPML1, generated a cationic whole-cell current that can be measured by patch clamp 11 .
We studied TRPML proteins by transiently expressing them in HEK293T cell lines. To monitor expression, TRPML channels were fused to enhanced green fluorescent protein (EGFP) at their N-termini. In response to a voltage step protocol, TRPML1 Va -expressing cells displayed strong inwardly rectifying step currents ( Fig. 1a & Supplementary Fig. 3 ) in a standard extracellular bath solution (a modified Tyrode's solution). TRPML1 Va -mediated current (I TRPML1-Va ) was 101 ± 8.6 pA/pF at −80 mV (mean ± SEM, n = 48). To mimic the acidic environments of lysosomes where the extracellular side (analogous to the intralysosomal lumenal side) of the wt TRPML1 protein is exposed to, extracellular solutions were adjusted to pH 4.6. No significant inward current was detected when NMDG + was the only major cation in the bath (pH 4.6; Fig. 1b) , indicating that I TRPML1-Va is a protonimpermeable cationic current 11 . Bath perfusion of 30 mM [Fe 2+ ] o (pH 4.6) to TRPML1 Vaexpressing cells induced large inwardly rectifying currents (Fig. 1c) Supplementary Fig. 4 ).
Both I Fe TRPML1-Va (Fig. 1e) and I TRPML1-Va 11 were enhanced at low pH. Compared to experiments conducted at physiological pH (pH 7.4), I Fe TRPML1-Va was enhanced ~2 fold at pH 4.6 (approximately the lumenal pH of lysosomes), respectively. In cells transfected with TRPML2 Va (a short splice variant; see Methods), large current (23.0 ± 3.8 pA/pF at −80 mV, n = 7) was evoked by 30 mM Fe 2+ (pH 4.6, Fig. 1e ). Similar to I TRPML1-Va , I TRPML2-Va was also strongly potentiated by low pH ( Supplementary Fig. 5 ). The ratio of I Fe /I Tyrode for TRPML2 Va was 139 ± 22% (at −80 mV, n = 7), which was even larger than the ratio for TRPML1 Va (72 ± 7 %, n = 11). In contrast with TRPML1 Va and TRPML2 Va , the ratio of I Fe /I Tyrode for TRPML3 Va was only 2.3 ± 0.2% (n = 8; Fig. 1f ). Thus Fe 2+ permeability is specific for TRPML1 and TRPML2, but not for the closely-related TRPML3. Cationic selectivity analysis suggested that TRPML1 Va was also permeable to most other divalent trace metals including Mn 2+ and Zn 2+ , but not to Fe 3+ (Supplementary Fig. 6 ). Detailed analyses of the permeation properties of TRPML1 Va suggested that the conduction mechanism of Fe 2+ resembled those of Na + and Ca 2+ (see Supplementary Figs. 7-9 ).
Next, we tested whether TRPML1's Fe 2+ permeability is impaired by ML4 mutations. More than 15 ML4 mutations have been identified, most of which are located in the transmembrane regions of TRPML1 ( Supplementary Fig. 10 (Fig. 2f) . In contrast, R403C-TRPML1 Va (Fig. 2g ) and F465L-TRPML1 Va showed no response to addition of 1 mM Fe 2+ . However, a higher concentration of Fe 2+ (10 mM) induced a slow but significant quenching. These results agree with the electrophysiological measurements of ML4 mutants, as well as the disease severity of ML4 patients carrying these mutations 5, [13] [14] [15] . We conclude that ML4 phenotypes result from a loss-of-function of TRPML1 with respect to Fe 2+ and/or Ca 2+ permeability.
To validate our use of TRPML1 Va as a model to extrapolate potential intracellular functions of wt TRPML1, and more importantly, to confirm whether wt TRPML1 conducts Fe 2+ from the lumen of LE/Ly into the cytosol, we performed patch clamp recordings directly on native LE/Ly membranes ( Fig. 3a & Supplementary Fig. 15 ; see methods summary). In TRPML1 Va -positive enlarged LE/Ly, large inwardly rectifying currents were seen under the lysosome-attached configuration (Fig. 3b, 3c ). The currents became smaller when the patch was excised (lysosome lumenal-side-out) and exposed to Tyrode's solution (Fig. 3c) . These large inwardly rectifying currents were not seen in TRPML1 Va -negative vacuoles, suggesting that these lysosomal currents are mediated by TRPML1 Va (hence are referred to as lysosomal I TRPML1-Va ). Note that inward lysosomal currents are actually currents that flow out of the lysosomes. Similar to I TRPML1-Va recorded at the plasma membrane, lysosomal I TRPML1-Va was impermeable to NMDG + or H + , but potentiated by low pH or by removal of divalent cations in the bath solution (Nominal Divalent-free) (Fig. 3d, 3e ). When the lumenal-side-out patches were exposed to 30 mM or 105 mM Fe 2+ solutions (pH 4.6), smaller and less rectifying currents were seen, resembling I Fe TRPML1-Va at the plasma membrane. These results suggest that TRPML1 Va behave similarly at both plasma membrane and lysosomal membranes. Likewise, ML4 mutant TRPML1 Va channels also behaved similarly as their plasma membrane counterparts ( Supplementary Fig. 16 ), consistent with our conclusion that ML4 mutations primarily affect the channel function of TRPML1.
Next we performed whole-lysosome recordings on enlarged LE/Ly expressing wt TRPML1 and TRPML1 Va . Significant inwardly rectifying currents were seen in wt TRPML1-positive LE/Ly (81.0 ± 9.0 pA/pF at −120 mV, n = 6; Fig. 3g ) with Nominal Divalent-free solution in the lumenal side (i.e., pipette solution), although the current amplitude is still one order of magnitude smaller than the whole-lysosome current recorded from TRPML1 Va -positive LE/Ly (1,713 ± 404 pA/pF at −120 mV, n = 4; Fig. 3h ). Since we were not able to record any significant whole-cell current from wt TRPML1-expressing HEK293T cells 11 , our results suggest that the Va mutation affects both channel gating and trafficking (between LE/Ly and the plasma membrane) of TRPML1. When isotonic (105 mM) Fe 2+ solution was included in the lumenal side of wt TRPML1-positive enlarged LE/Ly, inwardly rectifying currents with very positive reversal potential were observed (18 ± 4 pA/pF at −120 mV, n = 4; Fig. 3i ). Collectively, these results suggest that wt TRPML1 is a lysosomal Fe 2+ -permeable channel, and that the Va mutation does not alter the permeation properties of the TRPML1 channel.
Retention of Fe 2+ in LE/Ly due to loss/inactivation of Fe 2+ release mechanism may result in an insufficient supply of cytosolic Fe 2+ . We therefore measured the levels of free (chelatable) intracellular Fe 2+ in skin fibroblasts from a ML4 patient (TRPML1 −/− ) and the non-diseased parent (TRPML1 +/− ) using a fluorescence-based iron de-quenching imaging method (see Methods) 17 . Chelatable Fe 2+ levels were significantly lower in TRPML1 −/− cells compared to the control TRPML1 +/− cells (Fig. 4a, 4b ). TRPML1-deficient skin fibroblast cells exhibit auto-fluorescence (Fig. 4c) at excitation wavelengths between 440 nm and 500 nm, reminiscent of accumulated lipofuscin-like substances previously reported 18 . The auto-fluorescence observed was primarily localized in Lamp1 (a marker for LE/Ly)-positive compartments (Fig. 4c) , indicative of a lysosomal dysfunction in TRPML1 −/− cells. Lipofuscin, also referred to as an "aging pigment", is a non-degradable oxidized polymeric substance containing proteins, lipids, carbohydrates, and iron 19 . The production of lipofuscin is facilitated by increased intra-lysosomal Fe 2+ levels 19 . Our results suggest that an accumulation of auto-fluorescent lipofuscin-like molecules in TRPML1 −/− cells might result from impaired intra-lysosomal iron metabolism. Consistent with this, lysosomal iron staining experiments revealed that TRPML1 −/− cells exhibited higher lysosomal iron content than control cells (Supplementary Fig. 17 ).
We have demonstrated that TRPML1 plays a critical role in cellular iron homeostasis by showing the cytosolic Fe 2+ deficiency with concurrent intra-lysosomal iron overload in ML4 cells. ML4 cells exhibit a defect in the late endocytic pathway 10, 20, 21 , suggesting that TRPML1 may be required for Ca 2+ -dependent fusion/fission of LE/Ly. However, this defect in vesicular transport cannot explain the cytosolic Fe 2+ deficiency that we observed since the internalization and recycling of the transferrin receptor is normal in ML4 cells 20 , and lysosomal Fe 2+ release (into the cytosol) is most likely to be mediated directly by an ironconducting channel/transporter, as is the case for DMT1 22 . Therefore, by far the simplest explanation of our results is that the Fe 2+ release pathway between the cytosol and the lysosome lumen is blocked/inactivated in cells with ML4 mutations. While a ML4-inducedloss of Ca 2+ permeability may result in a defect of lysosomal trafficking and subsequent accumulation of various lipids in LE/Ly, the degradation of these materials is normal 20, 21 . Therefore, these accumulated substances would become most harmful only if they are oxidized to generate lipofuscin-like non-degradable materials in the presence of high intralysosomal Fe 2+ 19 . Lipofuscin-like molecules preferentially accumulate in post-mitotic cells such as muscle cells and neurons, which are primarily affected in ML4 patients 21 . Our work suggests that lysosome-targeting iron chelators might alleviate the degenerative symptoms of ML4 patients. From the cell biology perspective, a key question to ask is how TRPML channels are regulated by various cytosolic and lumenal factors, and/or by proteins and lipids in the LE/Ly membrane, especially those of which are known to be involved in endolysosomal trafficking.
Online Methods

Molecular biology and biochemistry
Full length mouse TRPML1 and TRPML3, and a short splicing variant of mouse TRPML2 (GeneBank # NP_001005846), were cloned into the EGFP-C2 vector (Clontech), the mCherry vector, or HA tag containing pcDNA3 as described previously 11 . No significant functional difference was observed among EGFP-tagged, mCherry-tagged, and HA-tagged TRPML Va constructs. ML4 mutants were constructed on a TRPML1 Va background using a site-directed mutagenesis kit (Qiagen). All constructs were confirmed by sequencing analysis and protein expression was verified by Western blotting. HEK293T cells were transiently transfected with wt TRPML1, TRPML1 Va , and ML4 mutants for electrophysiology, confocal imaging, 55 Fe 2+ uptake, and Fe 2+ quenching assays. TRPML1 Western blot analyses were performed with an anti-EGFP monoclonal antibody (Covance).
Confocal imaging
All images were taken using a Leica (TCS SP5) confocal microscope. Lamp1 antibody was from the Iowa Hybridoma Bank and LysoTracker was from Molecular Probes (Invitrogen).
Mammalian cell electrophysiology
Recordings were performed in transiently transfected HEK293T cells. 4 ). Low-pH NMDG + solution contained 150 mM NMDG, 10 mM Glucose, 10 mM MES, 10 HEPES (pH adjusted to 4.6 using methanesulfonic acid). "Isotonic" metal solutions contained 105 mM metal ions, 30 mM Glucose, 10 mM HEPES, 10 mM MES, 0-30 mM NMDG + (pH 4.6). Additional metal solutions (1, 3, 10, and 30 mM) derived from mixing "isotonic" solutions with low pH NMDG + solutions at various ratios. Monovalent (Nominal Divalent-free) solutions contained 10 mM glucose, 20 mM HEPES, 160 mM NaCl, 5 mM KCl (pH 7.4; free Ca 2+ <1-10 μM). All solutions were applied via a fast perfusion system to achieve a complete solution exchange within a few seconds. Data were collected using an Axopatch 2A patch clamp amplifier, Digidata 1440, and pClamp 10.0 software (Axon Instruments). Whole-cell currents and single channel recordings were digitized at 10 kHz and filtered at 2 kHz. Capacity current was reduced as much as possible using the amplifier circuitry. Series resistance compensation was 60-85%. All experiments were conducted at room temperature (~21-23°C) and all recordings were analyzed with pCLAMP10 (Axon Instruments, Union City, CA) and Origin 7.5 (Origin Lab, Northampton, MA).
Iron de-quenching imaging
Cultured skin fibroblast cells from a ML4 patient (TRPML1 −/− , clone WG0909) and corresponding heterozygous parent (TRPML1 +/− , clone WG0987) were obtained from the Repository for Mutant Human Cell Strains of Montreal Children's Hospital (Montreal, Canada). Fibroblast cells were loaded with 20 μM Phen Green SK (Molecular Probes) in culture medium at 37°C for 20 min followed by a 15 min wash. Cellular fluorescence was excited at 488 nm on the PTI ERP system. Quenching of fluorescence was induced by the addition of the membrane permeable transition metal chelator 2, 2′-Bipyridyl (5 mM) 17 . 4,4′-Bipyridyl, a 2, 2′-Bipyridyl analogue that cannot bind/chelate Fe 2+ , was used as a control. Since many variables such as dye loading may contribute to the variation of basal fluorescence (F) of PG SK, normalized change of fluorescence (ΔF/F) was used as readout to estimate the change of the cytosolic Fe 2+ levels.
Iron Uptake Assay
Iron uptake was measured as described previously 25 . Briefly, 30hrs after transfection, HEK293T cells were washed twice with pre-warmed PBS, and then incubated with 1ml of pre-warmed uptake assay buffer (25mM Tris, 25 mM Mes, 140 mM NaCl, 5.4 mM KCl, 5 mM glucose, 1.8 mM CaCl 2 , 800 μM MgSO4, 50 μM ascorbic acid, pH 5.8) containing 55 Fe-nitrilotriacetic acid (NTA, 1μM 55 Fe) at 37°C for 5min. 55 Fe-NTA was made by mixing 55 FeCl 3 (PerkinElmer) with 100mM NTA in a 1:50 molar ratio. Ascorbic acid (100 mM) was used to promote the formation and maintenance of ferrous (Fe 2+ ) iron (the pH was adjusted to pH 5.8). All uptake assays were performed with 20 μM Fe 2+ (with a 1:20 molar ratio for 55 FeCl 3 and FeSO4) at pH 5.8. Assays were stopped by the addition of 2ml ice-cold PBS. After washing three times with ice-cold PBS, the cells were detached and collected by adding 1ml 0.25% trypsin-EDTA. Parallel experiments were conducted at 0°C to measure the cell surface 55 Fe binding, which was subtracted from the values at 37 °C to obtain the net iron uptake. Cell-associated radioactivity was measured with liquid scintillation spectrometry.
Lysosomal iron staining
Lysosome iron was stained using a modified sulfide-silver method (SSM) 19 . Briefly, fibroblast cells were grown on coverslips and exposed to 50 μM Fe 3+ -Dextran overnight. Cells were then washed with PBS and fixed with 2% glutaraldehyde in 0.1 M Na-cacodylate buffer with 0.1 M sucrose (pH 7.2) for 1.5 h at room temperature (22°C). Next cells were sulfidated at pH ≈ 9 with 1% (w/v) ammonium sulfide in 70% (v/v) ethanol for 15 min. The development was then performed using a physical, colloid-protected developer containing silver-lactate and hydroquinone for 1-2h.
Reagents
2, 2′-BPD, 4, 4′-BPD, iron ascorbate, ferric chloride, iron dextran, and all other metal salts were from Sigma Chemicals (St. Louis, MO).
Data analysis
Most data are presented as the mean ± SEM. Statistical comparisons were made using analysis of variance (ANOVA). A P value < 0.05 was considered statistically significant.
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